TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03921606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (i-BMI)
Description: A brief MI via WhatsApp/WeChat

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individual face-to-face generic health advice
Description: Individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese). A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs.
Study: NCT02218762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Xinafoate DISKUS
Description: A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Xinafoate DISKUS
Description: A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match DISKUS
Description: A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match DISKUS
Description: A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
Study: NCT01696981

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Undergo questionnaire assessments
Study: NCT02218762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS
Description: A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
Study: NCT01696981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sigmoidoscopy
Description: Undergo a flexible sigmoidoscopy
Study: NCT02218762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS
Description: A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match ROTACAPS
Description: A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match ROTACAPS
Description: A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
Study: NCT04185740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CloudUPDRS - Tapping Task
Description: The TTT, consisting of two targets, will be presented on the screen of the smartphone. Participants will be instructed to alternate between the two targets using their index finger for 30 seconds. The task will always be performed with the left hand first and then with the right hand. The touch-sensitive screen of the smartphone will measure the timing of each touch event, its duration, the coordinates on the phone screen and the amount of pressure applied.
Study: NCT00904111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm®
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Patch
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Study: NCT00132522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 273066
Description: dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.~Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2.
Study: NCT03020212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
Study: NCT00470678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study: NCT02104141

Intervention type: DEVICE
Intervention: ROIA Interbody Cage with VerteBRIDGE plating
Study: NCT02727881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic solution
Description: Placebo Ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ranibizumab
Description: ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: ranibizumab
Study: NCT01008982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LimphoStat-B
Description: subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
Study: NCT04068649

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiation Therapy
Description: Undergo palliative RT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT01794026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion weighted magnetic resonance imaging
Description: for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
Study: NCT03617757

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HbA1c
Description: 2mL blood will be taken for analysis of HbA1c.
Study: NCT03009630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENB
Description: ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
Study: NCT01498731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge home
Description: Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
Study: NCT04776837

Intervention type: BEHAVIORAL
Intervention: Observational Cohort
Description: Patients will be followed by collecting clinical data, biospecimens, and quality of life assessment
Study: NCT01740635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EPIC WheelS Training Program
Description: Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
Study: NCT01798355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
Study: NCT03783039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SURGICEL Powder
Description: Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Powder, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL Original
Description: Surgeon to perform surgical procedure according to standard of care. If randomized to SURGICEL Original, the product will be be applied to the first appropriate TBS with mild or moderate bleeding in parenchyma or soft tissue where conventional methods of control (i.e. suture, ligature, cautery) are ineffective or impractical.
Study: NCT03638778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 3 mg
Description: Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 7 mg
Description: Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B 3 mg
Description: Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B 7 mg
Description: Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C 3 mg
Description: Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide C 7 mg
Description: Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D 3 mg
Description: Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide D 7 mg
Description: Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.
Study: NCT02031458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg IV every 3 weeks
Study: NCT01473524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.
Study: NCT00446641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: cilostazol 100mg twice a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 1 tablet twice a day matching for cilostazol
Study: NCT03949127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
Study: NCT01309373

Intervention type: OTHER
Intervention: Patient assessment
Description: 2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
Study: NCT04484506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone
Description: Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone
Description: Cyclophosphamide 750 mg/m2 intravenously on day 1, vincristine 1.4 mg/m2 intravenously on day1, etoposide 60mg/m2 intravenously on days 1-3; pegaspargase 2500IU/m2 intramuscularly on day 2, prednisone 100mg orally on days 1-5.
Study: NCT02799628

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: intervention
Description: intervention with recommendation and therapist introduction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: low back pain education, and physical therapy 3 times per week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: low back pain education, and physical therapy 3 times per week
Study: NCT01689324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: (ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis
Description: 0.5 mL, Intramuscular
Study: NCT00112684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02256189

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo one tablet daily
Study: NCT04329533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calm is a mindfulness meditation mobile app
Description: Mindfulness meditation is a self-management strategy that can be utilized to assist with the management of stress. Mindfulness meditation mobile applications, such as the Calm app, can be used to help manage stress, especially during this uncertain time.
Study: NCT02172846

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam radiation therapy (PBT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01473524

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets were administered orally once daily.
Study: NCT02389530

Intervention type: DRUG
Intervention: Fluorescein
Description: Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
Study: NCT01116310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)
Description: Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Bottles containing 60 capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Bottles containing 60 capsules.
Study: NCT03437629

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary cement based on Calcium Hydroxide
Description: Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Calcium Hydroxide; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MTA temporary cement
Description: Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Mineral trioxide aggregate; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
Study: NCT00668772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/Salmeterol
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium/Salmeterol QD + Salmeterol
Description: Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol Inhalation Powder, hard PE capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
Study: NCT00263601

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovit 6-grasses
Description: Subcutaneous injections

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injections
Study: NCT00661167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT02512276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telepharmacist intervention
Description: The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
Study: NCT03565991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: IV treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Oral treatment
Study: NCT04067011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500Mg Tablet
Description: Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100Mg Tablet
Description: Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: 0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
Study: NCT01461798

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: assessment of efficacy of Benecol yogurt
Description: Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo Yogurt
Description: Yogurt without the active principle

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: yogurt
Description: yogurt without plant stanols
Study: NCT00647907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.